Kopran Limited (NSE:KOPRAN)

India · Delayed Price · Currency is INR

280.75

+1.33 (0.48%)

Sep 24, 2026, 11:10 AM IST

Market Cap	13.49B +62.0%
Revenue (ttm)	7.00B +12.0%
Net Income	249.83M -28.4%
EPS	5.17 -28.4%
Shares Out	n/a
PE Ratio	53.98
Forward PE	n/a
Dividend	3.00 (1.07%)
Ex-Dividend Date	Aug 11, 2026

Volume	135,857
Open	279.42
Previous Close	279.42
Day's Range	277.22 - 283.27
52-Week Range	107.00 - 287.20
Beta	0.92
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Kopran

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, ur... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1958

Employees 1,156

Stock Exchange National Stock Exchange of India

Ticker Symbol KOPRAN

Full Company Profile

Financial Performance

In fiscal year 2026, Kopran's revenue was 6.81 billion, an increase of 8.23% compared to the previous year's 6.30 billion. Earnings were 257.31 million, a decrease of -33.26%.

Financial Statements